1
|
Carbonneau S, Sharma S, Peng L, Rajan V, Hainzl D, Henault M, Yang C, Hale J, Shulok J, Tallarico J, Porter J, Brogdon JL, Dranoff G, Bradner JE, Hild M, Guimaraes CP. An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell Chem Biol 2020; 28:802-812.e6. [PMID: 33333026 DOI: 10.1016/j.chembiol.2020.11.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 10/02/2020] [Accepted: 11/25/2020] [Indexed: 12/19/2022]
Abstract
The recent development of successful CAR (chimeric antigen receptor) T cell therapies has been accompanied by a need to better control potentially fatal toxicities that can arise from adverse immune reactions. Here we present a ligand-controlled CAR system, based on the IKZF3 ZF2 β-hairpin IMiD-inducible degron, which allows for the reversible control of expression levels of type I membrane proteins, including CARs. Testing this system in an established mouse xenotransplantation model for acute lymphoblastic leukemia, we validate the ability of the CAR19-degron to target and kill CD19-positive cells displaying complete control/clearance of the tumor. We also demonstrate that the activity of CAR19-degron can be regulated in vivo when dosing a US Food and Drug Administration-approved drug, lenalidomide.
Collapse
Affiliation(s)
- Seth Carbonneau
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Sujata Sharma
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Liaomin Peng
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Vaisakh Rajan
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Dominik Hainzl
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Martin Henault
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Chian Yang
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Jacob Hale
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Janine Shulok
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - John Tallarico
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Jeff Porter
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Glenn Dranoff
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - James E Bradner
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Marc Hild
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
| | | |
Collapse
|